Composition for treating intraventricular hemorrhage in preterm infants comprising mesenchymal stem cells
US-9539285-B2 · Jan 10, 2017 · US
Method for treating an inflammatory brain disease comprising administering a stem cell-derived exosome
US9919011B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9919011-B2 |
| Application number | US-201515126053-A |
| Country | US |
| Kind code | B2 |
| Filing date | Mar 18, 2015 |
| Priority date | Mar 18, 2014 |
| Publication date | Mar 20, 2018 |
| Grant date | Mar 20, 2018 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to a composition for treating inflammatory brain diseases, which includes stem cell-derived exosomes as an active ingredient. The stem cell-derived exosomes according to the present invention can be usefully applied to the treatment of inflammatory brain diseases, because the exosomes have outstanding therapeutic effects, including inhibiting cell death due to inflammation in nerve cells, increasing the survival rate in an inflammatory-brain-disease animal model, and substantially reducing brain damage and inflammatory cytokine levels due to inflammatory reactions such as edema.
First claim
Opening claim text (preview).
What is claimed is: 1. A method for treating an inflammatory brain disease, comprising: administering to a subject in need thereof an effective amount of exosome derived from a stem cell, wherein the inflammatory brain disease is selected from the group consisting of encephalitis, encephalomeningitis, and meningoencephalitis, and wherein the stem cell is a mesenchymal stem cell. 2. The method according to claim 1 , wherein the mesenchymal stem cell is derived from one or more tissues selected from the group consisting of umbilical cord, cord blood, bone marrow, fat, muscle, nerve, skin, amnion, and placenta. 3. The method according to claim 1 , wherein the encephalomeningitis is induced by one or more infectious agents selected from the group consisting of bacteria, parasites, fungi, protozoa, and viruses. 4. The method according to claim 3 , wherein the encephalomeningitis is bacterial infection-induced encephalomeningitis. 5. The method according to claim 1 , wherein the composition further comprises the internal contents of exosomes in addition to exosomes. 6. The method according to claim 1 , wherein the composition is administered orally, rectally, intravascularly, intramuscularly, subcutaneously, intrauterinely, cerebrovascularly, or intraventricularly. 7. The method according to claim 1 , wherein the stem cell is treated with thrombin. 8. The method according to claim 1 , wherein the exosome is administered in a pharmaceutical composition containing a pharmaceutically acceptable carrier.
Assignees
Inventors
Classifications
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title
for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia · CPC title
Drugs for disorders of the nervous system · CPC title
- A61K35/545Primary
Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9919011B2 cover?
- The present invention relates to a composition for treating inflammatory brain diseases, which includes stem cell-derived exosomes as an active ingredient. The stem cell-derived exosomes according to the present invention can be usefully applied to the treatment of inflammatory brain diseases, because the exosomes have outstanding therapeutic effects, including inhibiting cell death due to infl…
- Who is the assignee on this patent?
- Samsung Life Public Welfare Foundation
- What technology area does this patent fall under?
- Primary CPC classification A61K35/545. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Mar 20 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 3 related publications on this page (citations in our corpus or others sharing the same primary CPC).